Rocket Pharmaceuticals announces data from the Phase 1 clinical trial of RP A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy at ASGCT 2025
Rocket Pharmaceuticals a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced that the company will be… read more.
